Skip to main content

Table 4 Pooled incidences of selected toxicities

From: Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies

Adverse events Studies(t) Act-D-based regimen (n = 687) MTX-based regimen (n = 987)
Patients(n1/n2) % Patients(n1/n2) %
Hematologic disorders
 Anemia 2 46/129 35.7 37/127 29.1
 Leucocytopenia 3 27/208 13.0 24/182 13.2
 Neutropenia 5 31/259 12.0 26/264 9.8
 Thrombocytopnia 5 18/248 7.3 9/221 4.1
Gastrointestinal disorders
 Constipation 3 32/134 23.9 19/110 17.3
 Diarrhea 5 29/308 9.4 35/348 10.1
 Nausea 9 167/405 41.2 85/427 19.9
 Vomiting 9 92/436 21.1 43/449 9.6
Others
 Alopecia 7 69/232 29.7 19/207 9.2
 Anorexia 3 13/130 10.0 9/138 6.5
 Fatigue 3 84/134 62.7 60/110 54.5
 Liver toxicity 5 11/223 4.9 28/223 12.6
  1. Act-D Actinomycin D, MTX Methotrexate, t The number of studies reporting the toxicity, n Total number of enrolled patients, n1 The number of patients with adverse events, n2 the total number of patients from studies reporting the toxicity